AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • April 9th, 2021 • Elevation Oncology, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 10ths day of November 2020, by and among Elevation Oncology, Inc, a Delaware corporation formerly known as 14ner Oncology, Inc. (the “Company”), each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor,” and any subsequent investor that becomes a party to this Agreement in accordance with Section 6.9 hereof.
ELEVATION ONCOLOGY, INC.Initial Public Offering Participation Rights • April 9th, 2021 • Elevation Oncology, Inc. • Biological products, (no disgnostic substances)
This letter agreement (this “Letter”) will confirm our agreement that that, subject to and in consideration of the purchase of shares of Series B Preferred Stock of Elevation Oncology, Inc., a Delaware corporation (the “Company”), [•] (the “Investor”) shall be entitled to the following rights in connection with an IPO (as defined below) of the Company:
